William Blair research analyst Sami Corwin was quoted by Pharmaceutical Technologies in its coverage of the FDA’s new “pathway” for companies and the agency to use to move gene and cell therapies through approvals and to market faster.
While Corwin highlighted how the new pathway has “broad, positive implications” for companies producing gene and cell therapies, she noted it is “a bit more unclear” on how it can be implemented for companies dealing in rare and ultra-rare diseases.